Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2015. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons, specifically detailing changes in their interests in the Company's Ordinary Shares and American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director share allocations and does not contain financial performance data.
Material Changes
On December 31, 2014, Non-Executive Directors were provisionally allocated awards over Ordinary Shares and ADSs through the annual reinvestment of dividends paid throughout 2014. These allocations were calculated using an average price of £13.84 per Ordinary Share and $42.91 per ADS. The Company and Directors were informed of these allocations on January 5, 2015.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the specific number of Ordinary Shares and ADSs allocated to each Non-Executive Director listed in the filing.
- Confirm the average share prices (£13.84 and $42.91) used for the dividend reinvestment calculation.
- Review the full list of Non-Executive Directors to ensure all allocations are accounted for.